Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Pointe Capital Management LLC

Pointe Capital Management LLC boosted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 54.8% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 528 shares of the biopharmaceutical company’s stock after acquiring an additional 187 shares during the period. Pointe Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $376,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Rakuten Securities Inc. lifted its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after acquiring an additional 19 shares in the last quarter. FSA Wealth Management LLC purchased a new stake in shares of Regeneron Pharmaceuticals during the third quarter worth about $26,000. Fairfield Financial Advisors LTD acquired a new position in shares of Regeneron Pharmaceuticals in the third quarter valued at approximately $37,000. Truvestments Capital LLC purchased a new position in shares of Regeneron Pharmaceuticals during the third quarter valued at approximately $39,000. Finally, Valley Wealth Managers Inc. acquired a new stake in Regeneron Pharmaceuticals during the third quarter worth approximately $49,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Price Performance

REGN stock opened at $723.47 on Wednesday. The stock’s 50 day moving average is $698.84 and its two-hundred day moving average is $875.48. Regeneron Pharmaceuticals, Inc. has a 52-week low of $642.00 and a 52-week high of $1,211.20. The company has a market capitalization of $79.09 billion, a PE ratio of 18.90, a P/E/G ratio of 2.34 and a beta of 0.08. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN) last issued its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion during the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm earned $11.86 earnings per share. The business’s revenue was up 10.3% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current fiscal year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. The ex-dividend date is Thursday, February 20th. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.49%. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is presently 2.30%.

Analyst Upgrades and Downgrades

A number of brokerages have weighed in on REGN. Morgan Stanley reduced their price target on Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research note on Friday, November 1st. Bernstein Bank decreased their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research note on Tuesday, February 4th. Piper Sandler dropped their price objective on shares of Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an “overweight” rating for the company in a research note on Monday, January 27th. Canaccord Genuity Group downgraded shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Tuesday, December 17th. Finally, Oppenheimer decreased their price target on shares of Regeneron Pharmaceuticals from $1,150.00 to $1,000.00 and set an “outperform” rating on the stock in a report on Wednesday, November 6th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.